Vincristine Sulfate and Cyclophosphamide for Children With Metastatic Neuroblastoma

Thirty-eight children with metastatic neuroblastoma were given a combination of vincristine sulfate and cyclophosphamide in addition to standard surgical and radiotherapeutic management. The two agents were given intravenously on alternating weeks for 12 weeks or longer. Results were best in eight infants under 1 year, five of whom continued to survive free of disease for 16 months. The overall response rate in patients of all ages was 32% (nine out of 28), and the mean survival was 12 months. The combination of the two agents was effective.